Barrier Immunity Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, USA.
Metaorganism Immunity Section, Laboratory of Host Immunity and Microbiome, NIAID, NIH, Bethesda, MD, USA.
Mucosal Immunol. 2024 Oct;17(5):1089-1101. doi: 10.1016/j.mucimm.2024.07.008. Epub 2024 Jul 31.
Microbial translocation is a significant contributor to chronic inflammation in people living with HIV (PLWH) and is associated with increased mortality and morbidity in individuals treated for long periods with antiretrovirals. The use of therapeutics to treat microbial translocation has yielded mixed effects, in part, because the species and mechanisms contributing to translocation in HIV remain incompletely characterized. To characterize translocating bacteria, we cultured translocators from chronically SIV-infected rhesus macaques. Proteomic profiling of these bacteria identified cytosine-specific methyltransferases as a common feature and therefore, a potential driver of translocation. Treatment of translocating bacteria with the cytosine methyltransferase inhibitor decitabine significantly impaired growth for several species in vitro. In rhesus macaques, oral treatment with decitabine led to some transient decreases in translocator taxa in the gut microbiome. These data provide mechanistic insight into bacterial translocation in lentiviral infection and explore a novel therapeutic intervention that may improve the prognosis of PLWH.
微生物易位是 HIV 感染者(PLWH)慢性炎症的重要原因,并且与长期接受抗逆转录病毒治疗的个体的死亡率和发病率增加有关。使用治疗药物来治疗微生物易位的效果喜忧参半,部分原因是 HIV 中导致易位的物种和机制仍未完全阐明。为了表征易位细菌,我们从慢性 SIV 感染的恒河猴中培养易位剂。这些细菌的蛋白质组分析鉴定出胞嘧啶特异性甲基转移酶是一个共同特征,因此是易位的潜在驱动因素。用胞嘧啶甲基转移酶抑制剂地西他滨处理易位细菌,在体外显著抑制了几种细菌的生长。在恒河猴中,地西他滨口服治疗导致肠道微生物组中转位细菌的分类群一过性减少。这些数据为慢病毒感染中的细菌易位提供了机制上的见解,并探索了一种可能改善 PLWH 预后的新型治疗干预措施。